🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. A placebo matching Mepolizumab, Nucala 100 mg solution for injection in pre-filled syringe, A placebo matching Depemokimab, GSK3511294, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection, Nucala 100 mg solution for injection in pre-filled syringe, Fasenra 30 mg solution for injection in pre-filled syringe

    GlaxoSmithKline

    Severe asthma with an eosinophilic phenotype

    phase 3 small molecule active

    1 trial

  2. A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 3 other active

    1 trial

  3. A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-small cell lung cancer

    Mabxience Research SL

    advanced/metastatic non-squamous non-small cell lung cancer (NSCLC)

    phase 3 other active

    1 trial

  4. ABIRATERONE , DEGARELIX , Niraparib - capsule - 100 mg, RELUGOLIX , Niraparib tosylate monohydrate+ abiraterone acetate - Film coated tablet- 159.40 mg (eq. 100mg base)+ 500mg, Placebo for Niraparib, Prednison acis 5 mg, Tabletten, Niraparib tosylate monohydrate + abiraterone acetate - Film coated tablet- 79.90 mg (eq. 50mg base)+ 500mg, TECHNETIUM (99MTC) COMPOUNDS, -, Abiraterone acetate - tablet - 250 mg

    Janssen-Cilag International N.V.

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  5. ACARD 300 mg, 300 mg, tabletki, Microcrystalline cellulose, Native corn starch, Citric acid anhydrous (E330)

    COLLEGIUM PHARMACEUTICAL, INC

    aspirin-exacerbated respiratory disease

    phase 3 small molecule active

    1 trial

  6. ACICLOVIR VIATRIS 500 mg, poudre pour solution injectable (I.V.), CHLORURE DE SODIUM 0,9 % B. BRAUN, solution injectable en ampoule

    Pari Pharma GmbH

    Patients in ICU with invasive mechanical ventilation and HSV throat reactivation with 1 or no organ failures.

    phase 3 small molecule active

    1 trial

  7. ACIDE FOLIQUE CCD 5 mg, comprimé, PLACEBO D'ASPIRINE PROTECT, ASPIRINE PROTECT 100 mg, comprimé gastro-résistant, PLACEBO D'ACIDE FOLIQUE

    Pari Pharma GmbH

    Patients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in nature, occurs within a 72 hour window, and consists of a decrease in hearing of ≥30 decibels affecting at least 3 consecutive frequencies: 1. A history of an idiopathic and unilateral sudden decrease in hearing > 72 hours and <15 days. 2. A unilateral sensorineural hearing loss demonstrable on a pure‐tone audiogram at the time of entry into the trial. 3. No other neurological signs except the eight cranial nerve defect; no other types of hearing loss as conductive forms of hearing impairment. 4. No history of fluctuating sensorineural hearing loss or otologic disease.

    phase 3 small molecule active

    1 trial

  8. ACTILYSE 50mg placebo, ACTILYSE, poudre et solvant pour solution injectable et perfusion

    Pari Pharma GmbH

    intermediate-high-risk acute pulmonary embolism

    phase 3 small molecule active

    1 trial

  9. ACTILYSE, poudre et solvant pour solution injectable et perfusion, ACTILYSE, poudre et solvant pour solution injectable et perfusion, Metalyse 10,000 units powder and solvent for solution for injection, ACTILYSE, poudre et solvant pour solution injectable et perfusion, Metalyse 5 000 units (25 mg) powder for solution for injection

    Tour Hekla

    Acute ischaemic stroke due to basilar artery occlusion.

    phase 3 small molecule active

    1 trial

  10. ACTIQ (Oral transmucosal fentanyl citrate)

    Teva Pharma GmbH

    Breakthrough Pain

    phase 3 small molecule completed

    1 trial

  11. ACTISOUFRE, solution pour pulvérisation nasale/buccale en flacon pressurisé, Actisoufre Placebo

    Laboratoire HRA Pharma

    rhinosinusitis not requiring antibiotic therapy, rhinopharyngitis not requiring antibiotic therapy, Acute rhinitis not requiring antibiotic therapy

    phase 3 small molecule active

    1 trial

  12. ADRENALINE AGUETTANT 1 mg/ml, solution injectable en ampoule

    Novo Nordisk A/S

    Cardiorespiratory arrest at birth in full-term newborns

    phase 3 small molecule active

    1 trial

  13. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra Therapeutics

    Non-infectious Anterior Uveitis

    phase 3 small molecule completed

    1 trial

  14. AG-120/S95031 250mg film-coated tablet, Ivosidenib-matched Placebo Tablets

    The George Institute

    Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens

    phase 3 small molecule active

    1 trial

  15. AIN457

    Novartis Pharmaceuticals

    Non-infectious Uveitis

    phase 3 mab terminated

    1 trial

  16. AK112 Injection

    Summit Therapeutics

    Non-Squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 500 mg powder for concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Pembrolizumab, KEYTRUDA 25 mg/m

    Celltrion Healthcare Australia Pty Ltd

    Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. ALPELISIB, ALPELISIB, ALPELISIB

    Ningbo Cancer Hospital

    PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previously treated with trastuzumab

    phase 3 small molecule active

    1 trial

  19. AMIKACINE VIATRIS 1 g, poudre pour solution injectable en flacon, CHLORURE DE SODIUM 0,9 % COOPER, solution pour perfusion

    Tour Hekla

    Patients with ventilator-associated tracheobronchitis

    phase 3 small molecule active

    1 trial

  20. AMOXICILLIN TRIHYDRATE, SULFAMETHOXAZOLE AND TRIMETHOPRIM , LEVOFLOXACIN, AMOXICILLIN , AZITHROMYCIN, AZITHROMYCIN , IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., LEVOFLOXACIN

    Pari Pharma GmbH

    Young Adults and adults with R/R B-cell acute lymphoblastic leukemia (BCP-ALL) or a B cell lymphoma (BCL)

    phase 3 small molecule active

    1 trial

  21. AMOXICILLINE/ACIDE CLAVULANIQUE PANPHARMA 2 g/200 mg ADULTES, poudre pour solution injectable

    Pari Pharma GmbH

    Intensive care, Ventilator Associated Pneumonia

    phase 3 small molecule active

    1 trial

  22. ANHYDROUS DOCETAXEL, FLUOROURACIL, FLUOROURACIL, OXALIPLATIN, CALCIUM LEVOFOLINATE

    CERO THERAPEUTICS HOLDINGS, INC.

    Locally advanced or metastatic oesogastric adenocarcinoma

    phase 3 small molecule active

    1 trial

  23. ASCIMINIB HYDROCHLORIDE, ASCIMINIB

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia in chronic phase (CML-CP)

    phase 3 small molecule active

    1 trial

  24. ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP

    Astellas Pharma GmbH

    Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources